The FDA and Intellia Therapeutics are preparing a regulatory filing for product approval.
2 reports, 2 independent
Updated Aug 8
Gone quiet
- Reports
- 2
- Developments
- 4
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA and Intellia Therapeutics are preparing a regulatory filing for product approval.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Intellia Therapeutics is seeking FDA approval for its drug Lonvo-Z.Sub-event
Intellia expects the FDA to accept its rolling BLA filing.1 source
- FDA reviewed protocol amendment and interim safety data for a company's product.Sub-event
FDA and Intellia Therapeutics are preparing a regulatory filing for product approval.1 source
Keep exploring
The entities involved
- FDA
-
Intellia Therapeutics
It is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system.
Nothing else this week.
Related events
- FDA and Pfizer are seeking regulatory approval for their products.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.